Lilly’s next-generation obesity drug shows unprecedented weight loss but with a harsher side effect profile. This suggests a market segmentation strategy targeting the most severely obese patients, rather than competing directly with existing therapies for the broader population. The market is evolving beyond a simple race for maximum efficacy.

New treatments for obesity can cause a profound psychological shift. Patients who have spent a lifetime focused on restriction ("I can't eat that") suddenly find themselves in a new mindset focused on positive nourishment ("I need to fuel my body properly").

Contrary to Wall Street's focus on ever-increasing efficacy, real-world data shows GLP-1 users optimize for tolerability. They prefer a sustainable dose that offers health benefits without severe side effects, maximizing their ability to stay on the drug long-term.

Offering 12-month upfront subscriptions for weight-loss drugs creates a psychological 'sunk cost' for patients. This may compel them to continue using a medication despite adverse side effects or having already achieved their health goals, simply to 'get their money's worth,' potentially leading to negative health outcomes.

Unlike smoking, which is a behavior, obesity is a physiological outcome of complex genetic, environmental, and biological factors. The misconception that it's a behavior to be "changed" via willpower leads to ineffective strategies and harmful stigma.

Objecting to GLP-1s for outsourcing discipline is a flawed argument. Medicine has always sought to reduce human struggle, from anesthesia to antibiotics. Viewing GLP-1s as tools that improve biological function to free up human potential for other endeavors is consistent with this history.

Despite showing massive weight loss, new obesity drugs from Eli Lilly and others have high discontinuation rates due to side effects. This suggests the industry's singular focus on efficacy may be hitting diminishing returns, opening a new competitive front based on better patient tolerance and adherence.

While GLP-1 drugs can jumpstart weight loss by reducing appetite, they don't address poor food quality. If users simply eat less ultra-processed food, they risk severe protein and micronutrient deficiencies, leading to different long-term health consequences.

Treating obesity with drugs like Wegovy for a limited time, such as two years, is akin to only treating high cholesterol temporarily. This policy ignores the medical reality that obesity is a chronic disease requiring lifelong management, not a short-term condition.